Molecular Partners (Switzerland) Performance
| MOLN Stock | CHF 3.75 0.06 1.57% |
The company secures a Beta (Market Risk) of 0.38, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Molecular Partners' returns are expected to increase less than the market. However, during the bear market, the loss of holding Molecular Partners is expected to be smaller as well. At this point, Molecular Partners has a negative expected return of -0.35%. Please make sure to verify Molecular Partners' treynor ratio, potential upside, and the relationship between the total risk alpha and maximum drawdown , to decide if Molecular Partners performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Molecular Partners AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 133.7 M | |
| Total Cashflows From Investing Activities | -22.2 M |
Molecular |
Molecular Partners Relative Risk vs. Return Landscape
If you would invest 481.00 in Molecular Partners AG on December 13, 2024 and sell it today you would lose (106.00) from holding Molecular Partners AG or give up 22.04% of portfolio value over 90 days. Molecular Partners AG is generating negative expected returns and assumes 3.7442% volatility on return distribution over the 90 days horizon. Simply put, 33% of stocks are less volatile than Molecular, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Molecular Partners Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Partners' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Molecular Partners AG, and traders can use it to determine the average amount a Molecular Partners' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0942
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MOLN |
Estimated Market Risk
| 3.74 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Molecular Partners is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Molecular Partners by adding Molecular Partners to a well-diversified portfolio.
Molecular Partners Fundamentals Growth
Molecular Stock prices reflect investors' perceptions of the future prospects and financial health of Molecular Partners, and Molecular Partners fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Molecular Stock performance.
| Return On Equity | 0.62 | |||
| Return On Asset | 0.32 | |||
| Profit Margin | 0.62 % | |||
| Operating Margin | 0.61 % | |||
| Current Valuation | (39.23 M) | |||
| Shares Outstanding | 36.04 M | |||
| Price To Earning | 2.02 X | |||
| Price To Book | 0.89 X | |||
| Price To Sales | 1.19 X | |||
| Revenue | 9.33 M | |||
| EBITDA | (60.67 M) | |||
| Cash And Equivalents | 267.13 M | |||
| Cash Per Share | 8.22 X | |||
| Total Debt | 4.85 M | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 7.73 X | |||
| Cash Flow From Operations | (90.95 M) | |||
| Earnings Per Share | 3.53 X | |||
| Total Asset | 172.67 M | |||
About Molecular Partners Performance
Evaluating Molecular Partners' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Molecular Partners has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Molecular Partners has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland. MOLECULAR PARTNERS operates under Biotechnology classification in Switzerland and is traded on Switzerland Exchange. It employs 163 people.Things to note about Molecular Partners performance evaluation
Checking the ongoing alerts about Molecular Partners for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Molecular Partners help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Molecular Partners generated a negative expected return over the last 90 days | |
| Molecular Partners has high historical volatility and very poor performance | |
| The company reported the revenue of 9.33 M. Net Loss for the year was (63.78 M) with loss before overhead, payroll, taxes, and interest of (45.96 M). | |
| Molecular Partners AG has accumulated about 267.13 M in cash with (90.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 14.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Molecular Partners' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Molecular Partners' stock is overvalued or undervalued compared to its peers.
- Examining Molecular Partners' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Molecular Partners' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Molecular Partners' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Molecular Partners' stock. These opinions can provide insight into Molecular Partners' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Molecular Stock Analysis
When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.